[go: up one dir, main page]

Xiao et al., 2019 - Google Patents

Molecular detection and assessment of intervertebral disc degeneration via a collagen hybridizing peptide

Xiao et al., 2019

View PDF
Document ID
3592796879035902287
Author
Xiao L
Majumdar R
Dai J
Li Y
Xie L
Shen F
Jin L
Li X
Publication year
Publication venue
ACS biomaterials science & engineering

External Links

Snippet

During aging, wear, and tear of intervertebral discs, human discs undergo a series of morphological and biochemical changes. Degradation of extracellular matrix proteins, eg, collagen, arises as an important contributor and accelerator in this process. Existing …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Similar Documents

Publication Publication Date Title
Xiao et al. Molecular detection and assessment of intervertebral disc degeneration via a collagen hybridizing peptide
Grässel et al. Osteoarthritis: novel molecular mechanisms increase our understanding of the disease pathology
Eitner et al. Mechanisms of osteoarthritic pain. Studies in humans and experimental models
Luo et al. The minor collagens in articular cartilage
Goldring et al. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis
Sofat Analysing the role of endogenous matrix molecules in the development of osteoarthritis
Melrose et al. Mechanical destabilization induced by controlled annular incision of the intervertebral disc dysregulates metalloproteinase expression and induces disc degeneration
Mutsaers et al. Reversible molecular pathology of skeletal muscle in spinal muscular atrophy
Little et al. Post-traumatic osteoarthritis: from mouse models to clinical trials
Madry et al. Biological aspects of early osteoarthritis
Li et al. Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models
Bogdanovich et al. Myostatin blockade improves function but not histopathology in a murine model of limb‐girdle muscular dystrophy 2C
Valverde-Franco et al. Defects in articular cartilage metabolism and early arthritis in fibroblast growth factor receptor 3 deficient mice
Settle et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes
Scott et al. Increased versican content is associated with tendinosis pathology in the patellar tendon of athletes with jumper's knee
Tang et al. Effects of treadmill exercise on cerebral angiogenesis and MT 1‐MMP expression after cerebral ischemia in rats
US9969997B2 (en) Compositions and methods for inhibition of MMP8:MMP8-substrate interactions
Cheng et al. Inhibition of transforming growth factor β-activated kinase 1 prevents inflammation-related cartilage degradation in osteoarthritis
Huang et al. Alterations of ADAMTSs and TIMP‐3 in human nucleus pulposus cells subjected to compressive load: implications in the pathogenesis of human intervertebral disc degeneration
Ludwinski et al. Understanding the native nucleus pulposus cell phenotype has important implications for intervertebral disc regeneration strategies
Lewis et al. Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss
Yao et al. The effect of gut microbiota on the progression of intervertebral disc degeneration
KR20210057764A (en) Markers useful in reinforcement strategies for the treatment of osteoarthritis
Zhang et al. Matrilin‐2 is a widely distributed extracellular matrix protein and a potential biomarker in the early stage of osteoarthritis in articular cartilage
Franklin et al. Painful temporomandibular joint overloading induces structural remodeling in the pericellular matrix of that joint's chondrocytes